Bevacizumab in Complicated Anterior Segment Disease
Narrative Responses:
Purpose
To evaluate the efficacy of off-label topical Bevacizumab in managing three complicated cases with corneal NV and one case with limbal-conjunctival NV in impending recurrent pterygium.
Methods
4 young patients,(4 eyes), with acute and chronic neovascularistaion from infective (2 eyes), and inflammatory (2 eyes) origin, received topical Bevacizumab 5mg/ml or 10mg /ml, were used four times per day for the first month, frequency was adjusted if clinically indicated. Patients were followed up at regular intervals. Efficacy variables were NV area; the area of the total corneal covered by the vessels and adjacent conjunctiva. Safety was not a major variable, since the patients were young, healthy, and lacking any systemic co morbidities. Appropriate precautions were observed.The primary outcome was a change in NV.
Results
4 eyes of four patients, (2 females, 2 males), mean age of (29 years) were included in this case series. The patients showed significant reduction in NV area. Evaluation was assessed via comparison to previous anterior segment images taken at consultation visits.
Conclusion
Off label short-term use of topical Bevacizumab, may be effective in treating anterior segment NV secondary to various pathologies. This may provide an alternative or adjunctive measure to conventional therapies in use.